Abstract
Key functions of antibodies, such as viral neutralisation, depend on bivalent binding but the factors that influence it remain poorly characterised. Here, we develop and employ a new bivalent model to mechanistically analyse binding between >45 patient-isolated IgG1 antibodies interacting with SARS-CoV-2 RBD surfaces. Our method reproduces the monovalent on/off-rates and enables measurements of the bivalent on-rate and the molecular reach: the maximum antigen separation that supports bivalent binding. We find large variations in these parameters across antibodies, including variations in reach (22-46 nm) that exceed the physical antibody size (~15 nm) due to the antigen size. The bivalent model integrates all parameters, including reach and antigen density, to predict an emergent binding potency for each antibody that matches their neutralisation potency. Indeed, antibodies with similar monovalent affinities to the same RBD-epitope but with different reaches display differences in emergent bivalent binding that match differences in their neutralisation potency. Together, our work highlights that antibodies within an isotype class binding the same antigen can display differences in molecular reach that can substantially modulate their emergent binding and functional properties.
Introduction
Antibodies are Y-shaped molecules with two identical arms (Fabs) designed to bind to antigens. While bivalent binding—using both arms—is known to enhance an antibody's functional grip, accurately measuring and modeling this process has remained a challenge. Standard laboratory techniques like Surface Plasmon Resonance (SPR) typically rely on ordinary differential equations (ODEs) that assume a "well-mixed" environment. However, once the first arm of an antibody binds, the second arm is physically tethered, restricted to a specific "molecular reach."
This spatial constraint means traditional models often fail to explain why antibodies with similar monovalent affinities can have vastly different neutralization potencies. This study addresses this gap by defining and measuring "molecular reach" using a novel modeling framework.
Methods: A Spatial, Particle-Based Approach
To address the limitations of traditional kinetics, researchers developed a spatial, stochastic particle-based model. Unlike ODEs, this model explicitly accounts for the random distribution of antigens on a 2D surface and the physical reach of the antibody. By using the Gillespie method for simulations and a computationally efficient "surrogate model" (a pre-computed lookup table) for data fitting, the team could accurately extract bivalent binding parameters from SPR data.
The key parameter introduced is "molecular reach" ($ε$), representing the maximum distance between two antigens that supports bivalent binding. This parameter was validated using Steered Molecular Dynamics (SMD) simulations and experiments with PEG linkers of varying lengths to confirm the physical basis of the model's predictions.
Key Results: Molecular Reach and Neutralization Potency
The study analyzed a panel of 80 RBD-specific monoclonal antibodies isolated from COVID-19 patients. A major finding was that the molecular reach (22–46 nm) significantly exceeds the physical size of an IgG antibody (~15 nm). This is because the antigens themselves (RBDs) act as extensions, effectively increasing the bridgeable distance.
Furthermore, the model revealed that molecular reach is a critical determinant of neutralization. Even for antibodies targeting the same epitope with identical monovalent strength, variations in reach can lead to significant differences in overall binding potency on a viral surface. Interestingly, the density of Spike proteins on a real SARS-CoV-2 virion falls exactly into a "Goldilocks" zone where molecular reach matters most, maximizing the sensitivity of bivalent binding.
By incorporating the measured reach and the known density of Spike proteins on SARS-CoV-2, the model could calculate the neutralization potency ($IC_{50}$) of an antibody without ever needing to run a live-virus experiment. This suggests that the "emergent" binding property—how an antibody behaves in a bivalent, spatial context—is the true driver of its functional effectiveness.
Conclusion
This work highlights "molecular reach" as a fundamental biophysical property that modulates antibody function. By providing a framework to quantify this reach, the study opens new avenues for antibody engineering. Designing therapeutics with optimized reach could lead to more potent neutralizers for SARS-CoV-2 and other pathogens. Future research may extend this model to other antibody isotypes, such as IgM or IgA, further refining our understanding of the complex spatial dynamics of the immune response.
Summary updated